Evidence map›Paper›PMID 41143728›Full record

ReviewEuropean heart journal. Cardiovascular pharmacotherapy2025

Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus.

Heinz Drexel, Andreas Festa, Thomas A Schmidt, Bianca Rocca, Dobromir Dobrev, Stefan Agewall, Juan Tamargo, Susanne Kaser

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European heart journal. Cardiovascular pharmacotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Emerging therapies and evolving paradigms in cardiovascular pharmacotherapy.European heart journal. Cardiovascular pharmacotherapy · 2026
    Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Heinz DrexelAcademic Teaching Hospital Feldkirch, Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, Feldkirch 6800, Austria.ORCID 0000-0002-4677-9756
Andreas FestaAcademic Teaching Hospital Feldkirch, Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, Feldkirch 6800, Austria.
Thomas A SchmidtInstitute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Bianca RoccaDepartment of Medicine, LUM University, Casamassima (BA) 70010  Italy.ORCID 0000-0001-8304-6423
Dobromir DobrevInstitute of Pharmacology, West-German Heart and Vascular Centre, University Duisburg-Essen, DE 45122 Essen, Germany.ORCID 0000-0002-4612-117X
Stefan AgewallInstitute of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm 171 77, Sweden.
Juan TamargoDepartment of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto De Investigación Sanitaria Gregorio Marañón, Madrid 28040, Spain.
Susanne KaserDepartment of Internal Medicine I, Medical University of Innsbruck, Anichstrasse 35, Innsbruck 6020, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus typically has the lipid features of elevated trigycerides, reduced HDL-cholesterol (both parts of the metabolic syndrome) and average or slightly elevated LDL-cholesterol. In consequence of hypertriglyceridemia, LDL particles are small and dense and therefore highly atherogenic. Outcome studies reveal that LDL-C lowering drugs have an above-average efficacy in type 2 diabetes as compared with non-diabetic patients. A minor increase of glycaemia in statin trials does not impair the beneficial cardiovascular results. Non-statin lipid lowering drugs do not impair glycaemia. Type 2 diabetes mellitus is now considered a major indication for lipid lowering drugs, thus there is a high value of and no major limitation for those compounds.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2DyslipidemiasHypolipidemic AgentsBiomarkersBlood GlucoseComorbidityHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsRisk FactorsTreatment OutcomeBiomarkersBlood GlucoseHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsLipidsComorbiditiesDyslipidaemiaLipid-lowering drugsType 2 diabetes mellitus

Identifiers

PMID41143728
PMCPMC12705175

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.